Back to top
more

United Therapeutics (UTHR)

(Real Time Quote from BATS)

$240.15 USD

240.15
142,816

+5.68 (2.42%)

Updated Apr 24, 2024 12:16 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (147 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for UTHR

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

0 items in cart

United Therapeutics Corporation [UTHR]

Reports for Purchase

Showing records 341 - 360 ( 583 total )

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 341

07/21/2016

Company Report

Pages: 11

Q2 Preview: We Believe Consensus Is Achievable;Reiterate OUTPERFORM and $229 Price Target.

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 342

07/21/2016

Company Report

Pages: 11

Q2 Preview: We Project Top- and Bottom-line Beat on Solid Product Sales; Reiterate OUTPERFORM and $229 PT

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 343

07/13/2016

Daily Note

Pages: 4

UTHR v. World: Update on the Many Threads of IP Litigation

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 344

07/08/2016

Company Report

Pages: 7

Price: 24.95

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 345

07/05/2016

Company Report

Pages: 7

Price: 24.95

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 346

06/15/2016

Company Report

Pages: 11

Scales Are Tipping the Other Way; Downgrading to Neutral and Lowering PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 347

06/03/2016

Company Report

Pages: 7

Price: 24.95

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 348

05/31/2016

Daily Note

Pages: 43

June and Full Year 2016 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 349

05/09/2016

Daily Note

Pages: 43

May and Full Year 2016 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 350

05/02/2016

Company Report

Pages: 7

Price: 24.95

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 351

04/28/2016

Company Report

Pages: 9

Q1 Revenues Choppy but Annual Growth Remains Intact; Late-Stage Pipeline Could Provide Future Revenue Growth

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 352

04/25/2016

Company Report

Pages: 10

Q1 Preview: Consensus Revenue Slightly High but GAAP EPS Achievable In Our View

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 353

04/22/2016

Industry Report

Pages: 6

The Week Ahead in Life Sciences - Upcoming Events for the Week of April 25

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 354

04/05/2016

Company Report

Pages: 7

Price: 24.95

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 355

04/01/2016

Daily Note

Pages: 42

April and Full Year 2016 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 356

03/24/2016

Company Report

Pages: 8

Launch Timing for Remodulin Implantable Pump Now Up in the Air with Medtronic''s PMA Rejection; Reiterate OUTPERFORM but Reducing PT to $229.

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 357

03/04/2016

Company Report

Pages: 7

Price: 24.95

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 358

03/03/2016

Industry Report

Pages: 43

March and Full Year 2016 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 359

03/02/2016

Company Report

Pages: 9

Q4/FY 2015 Financials and Outlook: Increasing PAH Life Span Makes Prevalence A Growth Driver; Reiterate OUTPERFORM, Lower Price Target to $238

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 360

02/26/2016

Company Report

Pages: 6

A Transformative Deal Would Be The Best Defense

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party